NEXT-GENERATION POLYMER PLATFORM
Optimizing How Therapeutics Perform In The Body
Turning Good Molecules
Into Great Medicines
At Serina Therapeutics we're using next-generation polymer science to unlock the full potential of proven small molecule therapeutics.
At the heart of our innovation is POZ Platform™, a proprietary polymer platform that enables precise, controlled, and sustained drug exposure.
POZylation fundamentally improves how drugs perform in the body, extending their delivery and administration intervals, reducing side effects, and enhancing patient experience.
Backed by decades of research, a world-class team, and a powerful clinical and regulatory strategy, Serina is transforming the future of drug optimization.
The Power
of POZylation
By optimizing the pharmacokinetics of proven small molecules, POZylation enhances efficacy, reduces dosing frequency, and helps minimize side effects
Our lead candidate, SER-252 is a POZylated version of Apomorphine (POZ-apomorphine), a well characterized drug treatment for advanced Parkinson's disease. SER-252 exemplifies the power of the POZ Platform™ in action.
The POZ Platform™ is customizable, versatile and can be dosed via IV, SC or IM routes to address a broad range of clinical indications.
Introducing SER-252
(POZ-Apomorphine)
About Serina
Near-Linear
Release Kinetics
POZylation helps maintain consistent drug levels within this window by enabling controlled, sustained release. This means better symptom control, fewer side effects, and improved patient outcomes.
-
Drug is attached to multiple pendant groups
-
Single plasma enzyme releases the active drug
-
Can tune release profile of drug and drug load
-
Extends delivery and administration interval
-
Eliminates peak / trough profile for improved safety /efficacy
Redefining Treatment Paradigms for Advanced Parkinson’s Disease
POZ-Apomorphine is Partnered with Enable Injections
The highly differentiated target product profile that POZ Platform™ + enFuse™ enables has the potential to be a best-in-class, first line treatment of choice for advanced patients whose symptoms are inadequately controlled by current therapies.
10M
People in the world currently living with Parkinson’s disease
Every
9 Mins
A person is diagnosed with Parkinson's in US alone
50+
Years with no major clinical advances. Levadopa since 1967
SER-252 and SER-270
Are Just The Beginning
Our internal discovery and development work includes a focus on unlocking the potential of other molecules across a range of CNS indications and beyond. Our POZ Platform™ partners are at the forefront in advancing novel RNA medicines in vaccine immunology, cancer immunoRX, and gene therapy.
The Power Of the 505(b)2 Pathway
Our Latest News
Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)
HUNTSVILLE, AL, July 29, 2025
Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the advancement of its novel product candidate, SER-270, a proprietary POZ-conjugated vesicular monoamine transporter 2 (VMAT2) inhibitor in development for the treatment of tardive dyskinesia (TD).
Serina Therapeutics Makes Grant to New Employee Under Inducement Plan
HUNTSVILLE, AL, July 10, 2025
HUNTSVILLE, AL, July 1, 2025
HUNTSVILLE, AL, June 23, 2025
Opportunities
Serina Therapeutics, INC trades as publicly traded company on the NYSEAM Exchange under the symbol SER.
See our INVESTOR section for information and our investor perspectus.